Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Keytruda® (pembrolizumab) – New indication
June 24, 2020 - Merck announced the FDA approval of Keytruda (pembrolizumab), for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.
